HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: 2252011491v1 225/2/420    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Johnstone, P. A. S. Articles by Amling, C. L. Search for Related Content PubMed PubMed Citation Articles by Johnstone, P. A. S. Articles by Amling, C. L.

Effect of Race on Biochemical Disease-free Outcome in Patients with Prostate Cancer Treated with Definitive Radiation Therapy in an Equal-Access Health Care System: Radiation Oncology Report of the Department of Defense Center for Prostate Disease Research¹

¹ From the Naval Medical Ctr, San Diego, Calif (P.A.S.J., C.J.K., J.D., C.L.A.); Ctr for Prostate Disease Research, Dept of Surgery, Uniformed Service Univ, Bethesda, Md (L.S., H.W., J.W.M., D.G.M.); Walter Reed Army Medical Ctr, Washington, DC (J.W.M., D.G.M.); Naval Medical Ctr, Portsmouth, Va (D.D.M., L.K.); Madigan Army Medical Ctr, Tacoma, Wash (R.L.); National Naval Medical Ctr, Bethesda, Md (R.D., T.D.); Brooke Army Medical Ctr, San Antonio, Tex (M.G.B., J.F.); Malcolm Grow Air Force Medical Ctr, Andrews Air Force Base, Md (D.B.); Eisenhower Army Medical Ctr, Augusta, Ga (D.S.); and the Univ of California, San Diego (P.A.S.J.). From the 2001 RSNA scientific assembly. Received September 6, 2001; revision requested October 2; final revision received April 2, 2002; accepted April 30. Supported by the Ctr for Prostate Disease Research, a program of the Uniformed Services Univ of the Health Sciences administered by the Henry M. Jackson Foundation for the Advancement of Military Medicine and funded by the U.S. Army Medical Research and Materiel Command. Address correspondence to P.A.S.J., Naval Medical Center, San Diego, CA 92134-1014 (e-mail: pajohnstone@nmcsd.med.navy.mil).

PURPOSE: To report on the first collaboration of the Department of Defense Center for Prostate Disease Research concerned with the relationship between African American race and biochemical disease–free outcomes after definitive radiation therapy.

MATERIALS AND METHODS: Information from the medical records of 1,806 patients (1,349 white, 343 African American, 42 of "other" races, and 72 of "unknown" races) treated with definitive radiation therapy between 1973 and 2000 was reviewed. Patients receiving adjuvant hormonal therapy or postoperative adjuvant or salvage radiation therapy were excluded. Biochemical failure was calculated in over 96% of cases by using ASTRO criteria; patients with fewer than three follow-up visits were considered to have biochemical failure with a prostate-specific antigen (PSA) value more than 10-fold the previous value or with any value greater than 50.0 ng/mL. Median radiation therapy doses were similar. The median follow-up was 58.4 months. Kaplan-Meier tests, Cox proportional hazards regression analysis, and log-rank tests were used for data analysis.

RESULTS: There was no statistically significant difference in biochemical disease-free survival according to race when patients were stratified according to T stage. African American race conferred a negative prognosis for patients with lesions of Gleason biopsy score 7 (P = .004) but not for patients with lesions of Gleason score 2-4 (P = .14), 5-6 (P = .79), or 8-10 (P = .86). Similarly, African American race conferred a negative prognosis in patients with PSA values of 20.1–50.0 ng/mL (P = .01) at presentation but not in patients with PSA values less than or equal to 4.0 ng/mL (P = .84), 4.1–10.0 ng/mL (P = .71), 10.1–20.0 ng/mL (P = .75), or above 50.0 ng/mL (P = .15) at presentation. At multivariate analysis, race was not a statistically significant predictor of outcome.

CONCLUSION: In the equal-access health care system of the Department of Defense, African American race is not associated with a consistently negative prognosis in patients treated with definitive radiation therapy for prostate cancer. Race appears to confer a negative prognosis only in patients with advanced disease at presentation.

Index terms: Data analysis • Prostate neoplasms, 844.32 • Prostate neoplasms, therapeutic radiology, 844.1269

This article has been cited by other articles:

				B. A. Spencer, D. C. Miller, M. S. Litwin, J. D. Ritchey, A. K. Stewart, R. L. Dunn, E. G. Gay, H. M. Sandler, and J. T. Wei Variations in Quality of Care for Men With Early-Stage Prostate Cancer J. Clin. Oncol., August 1, 2008; 26(22): 3735 - 3742. [Abstract] [Full Text] [PDF]

				A. A. Konski, T. F. Pajak, B. Movsas, J. Coyne, J. Harris, C. Gwede, A. Garden, S. Spencer, C. Jones, and D. Watkins-Bruner Disadvantage of Men Living Alone Participating in Radiation Therapy Oncology Group Head and Neck Trials J. Clin. Oncol., September 1, 2006; 24(25): 4177 - 4183. [Abstract] [Full Text] [PDF]

				T. K. Johnson, F. D. Gilliland, R. M. Hoffman, D. Deapen, D. F. Penson, J. L. Stanford, P. C. Albertsen, and A. S. Hamilton Racial/Ethnic Differences in Functional Outcomes in the 5 Years After Diagnosis of Localized Prostate Cancer J. Clin. Oncol., October 15, 2004; 22(20): 4193 - 4201. [Abstract] [Full Text] [PDF]

				A. I. Neugut, A. C. Chen, and D. P. Petrylak The "Skinny" on Obesity and Prostate Cancer Prognosis J. Clin. Oncol., February 1, 2004; 22(3): 395 - 398. [Full Text] [PDF]

				R. P. Caruso, B. Levinson, J. Melamed, R. Wieczorek, S. Taneja, D. Polsky, C. Chang, A. Zeleniuch-Jacquotte, K. Salnikow, H. Yee, et al. Altered N-myc Downstream-Regulated Gene 1 Protein Expression in African-American Compared with Caucasian Prostate Cancer Patients Clin. Cancer Res., January 1, 2004; 10(1): 222 - 227. [Abstract] [Full Text] [PDF]